Porcine carotid vascular effects of eletriptan (UK-116,044): A new 5- HT(1B/1D) receptor agonist with anti-migraine activity

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 358, Issue 2, 1998, Pages 212-219

  Willems, Edwin ^a   De Vries, Peter ^a   Heiligers, Jan P C ^a   Saxena, Pramod R ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

5 HT receptors; Arteriovenous anastomoses; Arteriovenous shunts; Carotid artery; Eletriptan; Migraine headache; Pig; Sumatriptan

Indexed keywords

ELETRIPTAN; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD FLOW; CAROTID ARTERY FLOW; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HEMODYNAMICS; MIGRAINE; NONHUMAN; SWINE;

EID: 0031686668     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00005245     Document Type: Article

References (51)

1. 1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 90:408-412
2. Bouchelet I, Cohen Z, Case B, Seguela P, Hamel E (1996) Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 50:219-223
3. Brändli P, Loffler BM, Breu V, Osterwalder R, Maire JP, Clozel M (1996) Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 64:315-322
4. 1D antagonists. J Med Chem 37:2253-2257
5. 1D receptor antagonist. Br J Pharmacol 118:85-92
6. 1B/1D and novel receptors. Br J Pharmacol, in press
7. 1B/1D receptors. Eur J Pharmacol, in press
8. 1-like receptors. Br J Pharmacol 104:183-189
9. 1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol 102:323-330
10. 1D receptors involved? Naunyn Schmiedebergs Arch Pharmacol 345:509-515
11. Den Boer MO, Van Woerkens LJ, Somers JA, Duncker DJ, Lachmann B, Saxena PR, Verdouw PD (1993) On the preservation and regulation of vascular tone in arteriovenous anastomoses during anesthesia. J Appl Physiol 75:782-789
12. Diener HC (1995) Substance-P antagonist RPR100893-201 is not effective in human migraine attacks. 6th International Headache Research Seminar, Copenhagen, 17-19 November 1995
13. 1A receptor agonist flesinoxan in the cat. J Cardiovasc Pharmacol 14:770-776
14. Goldstein J, Dahlof CGH, Diener HC, Olesen J, Schellens R, Senard JM, Simard D, Steiner TJ (1996) Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Cephalalgia 16:497-502
15. Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT (1997) Ineffectiveness of neurokinin-antagonist in acute migraine: a crossover study. Cephalalgia 17:785-790
16. 1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation. Br J Pharmacol 116:2385-2390
17. 1D-like' receptors. Cephalalgia 16:386
18. Gupta P, Napier C, Scatchard J, Shepperson N, Wallis R (1997) Further characterzation of the in vitro pharmacology of eletriptan. Cephalalgia 17:413
19. 1Dβ receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 44:242-246
20. Heyck H (1969) Pathogenesis of migraine. Res Clin Stud Headache 2:1-26
21. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 46:157-203
22. 1-like receptor in dog isolated saphenous vein. Br J Pharmacol 94:1123-1132
23. Humphrey PPA, Apperley E, Feniuk W, Perren MJ (1990) A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena PR, Wallis DI, Wouters W, Bevan P (eds) Cardiovascular pharmacology of 5-hydroxytryptamine: prospective therapeutic applications. Kluwer Academic Publishers, Dordrecht, pp 416-431
24. Jackson NC (1996) A comparison of oral eletriptan (UK-166,044) (20-80 mg) and oral sumatriptan (100 mg) in the acute treatment of migraine. Cephalalgia 16:368
25. 1B receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 8:2237-2240
26. 3H]alniditan. Mol Pharmacol 50:1567-1580
27. May A, Gijsman HJ, Wallnöfer A, Jones R, Diener HC, Ferrari MD (1996) Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 67:375-378
28. 1D-like' receptor partial agonist. Cephalalgia 17:414
29. Olesen J, Abel S, Allen M, Allis P, Eve M, Kleinermans D, Lahuerta J, Pollack S, Soelberg-Sorensen P, Steiner T (1997) The efficacy, safety and pharmacokinetics of eletriptan following intravenous administration to patients experiencing migraine with or without aura. Cephalalgia 17:415
30. 1B/D receptor agonists in the normotensive rat. Br J Pharmacol 123:205-214
31. 1B/D receptor antagonist CR127935. CNS Drug Rev 2:415-428
32. 1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 61:2117-2126
33. 1D receptors. Naunyn Schmiedebergs Arch Pharmacol 356:312-320
34. Roon K, Diener HC, Ellis P, Hettiarachchia J, Poole P, Christiansen L, Ferrari MD, Olesen J (1997) CP-122,207 blocks neurogenic inflammation, but is ineffective in aborting migraine-attacks: results of two controlled clinical trials. Cephalalgia 17: 245
35. Saxena PR (1995) Cranial arteriovenous shunting, an in vivo animal model for migraine. In: Olesen J, Moskowitz MA (eds) Experimental headache models. Philadelphia, pp 189-198
36. Saxena PR, Verdouw PD (1982) Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J Physiol (Lond) 332:501-520
37. 1A receptor agonism: a novel mechanism for antihypertensive action. Trends Pharmacol Sci 11:95-96
38. Saxena PR, Schamhardt HC, Forsyth RP, Loeve J (1980) Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput Programs Biomed 12:63-84
39. Saxena PR, De Vries P, Heiligers JPC, Maassen VanDenBrink A, Bax WA, Barf T, Wikström H (1996) Investigations with GMC2021 in experimental models predictive of antimigraine activity and coronary side-effect potential. Eur J Pharmacol 312:53-62
40. 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Naunyn Schmiedebergs Arch Pharmacol 355:295-302
41. 1D receptor agonists in development for the acute treatment of migraine. In: Olesen J, Tfelt-Hansen P (eds) Headache treatment: trial methodology and new drugs. Lippicott-Raven Publishers Philadelphia, New York, pp 229-241
42. 1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential. Eur J Pharmacol, in press
43. 1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto-and heteroreceptors. Naunyn Schmiedebergs Arch Pharmacol 356:321-327
44. 1D receptor subtype. J Pharmacol Exp Ther 252:387-395
45. Shepheard SL, Williamson DJ, Williams J, Hill RG, Hargreaves RJ (1995) Comparison of the effects of sumatriptan and the NKI antagonist CP-99,994 on plasma extravasation in Dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology 34:255-261
46. 1D receptor antagonist. Behav Brain Res 73:157-161
47. Steel RGD, Torrie JH (1980) Principles and procedures of statistics. A biomedical approach, 2nd edn. McGraw-Hill Kogakusha, Tokyo
48. The Subcutaneous Sumatriptan International Study Group (1991) Treatment of migraine attacks with sumatriptan. N Engl J Med 325:316-321
49. Visser WH, Vriend RH de, Jaspers MW, Ferrari MD (1996) Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 47:46-51
50. 1D agonist properties. Cephalalgia 17:404
51. 1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea-pig dura mater. Neuropharmacology 36:83-91